Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: Hospital Emergency Department vs. Primary Care Center (ObsATBGignaUrg)

July 13, 2026 updated by: University Hospital, Montpellier

Comparative Study of Adherence to Antibiotic Therapy Among Pediatric Patients: The Gignac Primary Care Medical Center Versus the Pediatric Emergency Department of Montpellier University Hospital (CHU Montpellier).

This study was initiated because of the limited litterature available on this topic. The objective was to compare adherence to antibiotic therapy among a pediatric population treated in two healthcare settings in France: the Gignac Health Center, a primary care facility, and the Pediatric Emergency Department of Montpellier University Hospital. This observational study assessed treatment adherence through a telephone questionnaire administered to parents after the theorical end of the treatment.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

191

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Pediatric patients presenting to the Gignac Primary Care Health Center or the Pediatric Emergency Department of Montpellier University Hospital with a suspected bacterial infection and considered eligible for an outpatient oral antibiotic prescription.

Description

Inclusion Criteria:

  • Children aged 3 months to 16 years
  • Receiving an outpatient oral antibiotic prescription
  • Diagnosed with an acute bacterial infection

Exclusion Criteria:

  • Unemancipated minors presenting without a parent or legal guardian.
  • Participation in another clinical research study with an ongoing exclusion period
  • Refusal to participate after the reflection period
  • Parents unable to understand the study information (e.g., language barrier or cognitive impairment)
  • Not affiliated with, or not a beneficiary of, a national health insurance scheme
  • Pregnant or breastfeeding female participants

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Pediatric patients prescribed antibiotic for acute bacterial infection at the Gignac Health center
Pediatric patients aged 3 months to 16 years presenting with an acute bacterial infection and prescribed an outpatient antibiotic treatment were eligible for inclusion. Parents were contacted by telephone between 15 and 21 days after the antibiotic prescription to assess treatment adherence.
Children prescribed antibiotic for acute bacterial infection at pediatric emergency of Montpellier
Pediatric patients aged 3 months to 16 years presenting with an acute bacterial infection at pediatric emergency department Montpellier University Hospital and prescribed an outpatient antibiotic treatment were eligible for inclusion. Parents were contacted by telephone between 15 and 21 days after the antibiotic prescription to assess treatment adherence.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients who adhered to the antibiotic prescription provided by the general practitioner (GP) or the emergency physician (University Hospital)
Time Frame: The study period extended from the initial consultation (antibiotic prescription) to 21 days after the prescription, depending on the prescribed treatment duration.
Treatment adherence was considered satisfactory when at least 80% of the prescribed antibiotic course was taken
The study period extended from the initial consultation (antibiotic prescription) to 21 days after the prescription, depending on the prescribed treatment duration.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Montpellier

Investigators

  • Study Director: Eric E JEZIORSKI, Professor of Medicine at Montp, Pediatric Emergency Department, Montpellier University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

September 1, 2028

Study Registration Dates

First Submitted

July 13, 2026

First Submitted That Met QC Criteria

July 13, 2026

First Posted (Actual)

July 17, 2026

Study Record Updates

Last Update Posted (Actual)

July 17, 2026

Last Update Submitted That Met QC Criteria

July 13, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RECHMPL25_0564

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Impetigo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe